Ser949
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser949  -  PASK (human)

Site Information
RTRLFLAsLPGstHs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 14160727

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 1 )
Disease tissue studied:
cervical cancer ( 2 ) , cervical adenocarcinoma ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
RHEB (human) ( 1 )
Kinases, in vitro:
mTOR (human) ( 1 )
Treatments:
nocodazole ( 2 ) , rapamycin ( 1 ) , siRNA ( 1 ) , Torin1 ( 1 )

References 

1

Kikani CK, et al. (2019) Activation of PASK by mTORC1 is required for the onset of the terminal differentiation program. Proc Natl Acad Sci U S A 116, 10382-10391
31072927   Curated Info

2

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

3

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info